Dolutegravir is an HIV integrase strand transfer inhibitor (INSTI) that does not require pharmacokinetic boosting, has a long half-life allowing for once-daily dosing in treatment-naive patients ...

Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer immunotherapy, including Merck & Co. The US regulator cleared BMS' LAG-3 drug relatlimab ...

Excluding Greater China, MSD gains rights for developing, manufacturing and commercialising the therapy globally. Credit: Copyright © 2025 Merck & Co., Inc., Rahway ...

It is the second drug in the PD-1/PD-L1 inhibitor class to be cleared in a subcutaneous injection form by the FDA after Roche's Tecentriq Hybreza (atezolizumab and hyaluronidase) – which got a ...

Summary of JAK Inhibitor Selection and Transplant Considerations in Myelofibrosis JAK Inhibitor Landscape All 4 JAK inhibitors (ruxolitinib, fedratinib, pacritinib, momelotinib) are approved in a line ...

A once-daily oral PCSK9 inhibitor reduced LDL in patients with hypercholesterolemia. Safety and tolerability profiles were favorable, according to investigators. CHICAGO — In a phase 2b study ...

1Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan. 2Department of Obstetrics and Gynecology, The First Affiliated Hospital of Harbin Medical ...

Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 (TYK2) inhibitor as a dermatology treatment in Japan. The drug in ...

1Department of Molecular and Cellular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

He must be the catalyst and not an inhibitor. All his actions must be impelled, keeping in mind the dignity of the high constitutional office.” India needs fair, non-hyphenated and questioning ...